Jemal, A, Siegel, R, Ward, E. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.CrossRefGoogle ScholarPubMed

Jemal, A, Siegel, R, Ward, E. Cancer Statistics, 2009. CA Cancer J Clin. 2009; 59(4):225–249.CrossRefGoogle ScholarPubMed

Gouda, I, Mokhtar, N, Bilal, D. Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Natl Canc Inst. 2007;19(2):158–162.Google ScholarPubMed

Pelucchi, C, Bosetti, C, Negri, E. Mechanisms of disease: the epidemiology of bladder cancer. Natl Clin Pract Urol. 2006;3(6):327–340.CrossRefGoogle ScholarPubMed

Stein, JP, Lieskovsky, G, Cote, R. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–675.CrossRefGoogle ScholarPubMed

der Maase, H, Sengelove, L, Roberts, JT. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–4608.CrossRefGoogle Scholar

Prout, Jr GR, Wesley, MN, Yancik, R. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer. 2005;104(8):1638–1647.CrossRefGoogle ScholarPubMed

Herr, HW, Schwalb, DM, Zhang, ZF. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995;13(6):1404–1408.CrossRefGoogle ScholarPubMed

Joudi, FN, Smith, BJ, O';Donnell, MA. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175(5):1634–1639; discussion 1639–1640.CrossRefGoogle ScholarPubMed

Herr, HW. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy. Urology. 2007;70(1):65–68.CrossRefGoogle ScholarPubMed

Aa, MN, Steyerberg, EW, Sen, EF. Patients'; perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. BJU Int. 2008;101(9):1106–1110.Google ScholarPubMed

Wu, XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5(9):713–725.CrossRefGoogle ScholarPubMed

Clark, PE, Stein, JP, Groshen, SG. Radical cystectomy in the elderly: comparison of clinical outcomes between younger and older patients. Cancer. 2005;104(1):36–43.CrossRefGoogle ScholarPubMed

Clark, PE, Stein, JP, Groshen, SG. Radical cystectomy in the elderly: comparison of survival between younger and older patients. Cancer. 2005;103(3):546–552.CrossRefGoogle ScholarPubMed

Hollenbeck, BK, Miller, DC, Taub, D. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology. 2004;64(2):292–297.CrossRefGoogle ScholarPubMed

Donat, SM, Siegrist, T, Cronin, A. Radical cystectomy in octogenarians–does morbidity outweigh the potential survival benefits?J Urol. 2010;183:2171–2177.CrossRefGoogle ScholarPubMed

Koppie, TM, Serio, AM, Vickers, AJ. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer. 2008;112(11):2384–2392.CrossRefGoogle ScholarPubMed

Weizer, AZ, Joshi, D, Diagnault, S. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol. 2007;177(4):1287–1293.CrossRefGoogle ScholarPubMed

Hagan, MP, Winter, KA, Kaufman, DS. RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57(3):665–672.CrossRefGoogle ScholarPubMed

Rodel, C, Grabenbauer, GG, Kuhn, R. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20(14):3061–3071.CrossRefGoogle ScholarPubMed

Shipley, WU, Kaufman, DS, Zehr, E. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002;60(1):62–67.CrossRefGoogle ScholarPubMed

Kaufman, DS, Winter, KA, Shipley, WU. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial. Oncologist. 2000;5(6):471–476.CrossRefGoogle ScholarPubMed

Sauer, R, Birkenhake, S, Kuhn, R. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 1998;40(1):121–127.CrossRefGoogle ScholarPubMed

Tester, W, Caplan, R, Heaney, J. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996;14(1):119–126.CrossRefGoogle ScholarPubMed

Tester, W, Porter, A, Asbell, S. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys. 1993;25(5):783–790.CrossRefGoogle ScholarPubMed

Fernando, SA, Sandler, HM. Multimodality bladder preservation therapy for muscle-invasive bladder tumors. Semin Oncol. 2007;34(2):129–134.CrossRefGoogle ScholarPubMed

Rodel, C, Weiss, C, Sauer, R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol. 2006;24(35):5536–5544.CrossRefGoogle ScholarPubMed

Kent, E, Sandler, H, Montie, J. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol. 2004;22(13):2540–2545.CrossRefGoogle ScholarPubMed

Oh, KS, Soto, , Smith, DC. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys. 2009;74(2):511–517.CrossRefGoogle ScholarPubMed

Herman, JM, Smith, DC, Montie, J. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology. 2004;64(1):69–73.CrossRefGoogle ScholarPubMed

Zietman, AL, Sacco, D, Skowronski, U. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003;170(5):1772–1776.CrossRefGoogle ScholarPubMed

Loehrer Sr, PJ, Einhorn, LH, Elson, PJ. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066–1073.CrossRefGoogle Scholar

Logothetis, CJ, Dexeus, FH, Finn, L. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. J Clin Oncol. 1990;8:1050– 1055.CrossRefGoogle ScholarPubMed

Saxman, SB, Propert, KJ, Einhorn, LH. Long term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial cancer: a cooperative group study. J Clin Oncol. 1997;15:2564–2569.CrossRefGoogle ScholarPubMed

Sternberg, CN, Yagoda, A, Scher, HI. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer. 1989;64(12):2448–2458.3.0.CO;2-7>CrossRefGoogle ScholarPubMed

der Maase, H, Hansen, SW, Roberts, JT. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–3077.CrossRefGoogle Scholar

Grossman, HB, Natale, RB, Tangen, CM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–866.CrossRefGoogle ScholarPubMed

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361(9373):1927–1934.CrossRef

,Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International Collaboration of Trialists. Lancet. 1999;354(9178):533–540.Google Scholar

,Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev. 2005;CD005246.

Studer, U, Bacchi, M, Biederman, C. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol. 1994;152:81–84.CrossRefGoogle ScholarPubMed

Skinner, DG, Daniels, JR, Russell, CA. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991;145(3):459–464; discussion 464–467.CrossRefGoogle ScholarPubMed

Freiha, F, Reese, J, Torti, FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol. 1996;155(2):495–499; discussion 499–500.CrossRefGoogle ScholarPubMed

Stockle, M, Meyenburg, W, Wellek, S. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy: results of a controlled prospective study. J Urol. 1992;148(2 Pt 1):302–066; discussion 306–307.CrossRefGoogle ScholarPubMed

Stockle, M, Meyenburg, W, Wellek, S. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further experience. J Urol. 1995;153:47–52.CrossRefGoogle Scholar

,Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48(2):189–199; discussion 199–201.CrossRefGoogle Scholar

Milowsky, MI, Stadler, WM, Bajorin, DF. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU Int. 2008;102(9 Pt B):1339–1344.CrossRefGoogle ScholarPubMed

Bellmunt, J, Ribas, A, Eres, N. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997;80(10):1966–1972.3.0.CO;2-W>CrossRefGoogle ScholarPubMed

Petrioli, R, Frediani, B, Manganelli, A. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: a randomized phase II study. Cancer. 1996;77(2):344–351.3.0.CO;2-1>CrossRefGoogle ScholarPubMed

Dogliotti, L, Carteni, G, Siena, S. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007;52(1):134–141.CrossRefGoogle ScholarPubMed

Fehrman-Ekholm, I, Skeppholm, L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol. 2004;38(1):73–77.CrossRefGoogle ScholarPubMed

Dash, A, Galsky, MD, Vickers, AJ. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3):506–513.CrossRefGoogle ScholarPubMed

Agrawal, Y, Platz, EA, Niparko, JK. Prevalence of hearing loss and differences by demographic characteristics among US adults: data from the National Health and Nutrition Examination Survey, 1999–2004. Arch Intern Med. 2008;168(14):1522–1530.CrossRefGoogle ScholarPubMed

Rademaker-Lakhai, JM, Crul, M, Zuur, L. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol. 2006;24(6):918–924.CrossRefGoogle ScholarPubMed

Guralnik, JM, Ferrucci, L, Simonsick, EM. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332(9):556–561.CrossRefGoogle ScholarPubMed

Guralnik, JM, Simonsick, EM, Ferrucci, L. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85–M94.CrossRefGoogle Scholar

Inzitari, M, Carlo, A, Baldereschi, M. Risk and predictors of motor-performance decline in a normally functioning population-based sample of elderly subjects: the Italian Longitudinal Study on Aging. J Am Geriatr Soc. 2006;54(2):318–324.CrossRefGoogle Scholar

Bamias, A, Efstathiou, E, Moulopoulos, . The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol. 2005;16(2):307–313.CrossRefGoogle ScholarPubMed

Castagneto, B, Zai, S, Marenco, D. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology. 2004;67(1):27–32.CrossRefGoogle ScholarPubMed

Bamias, A, Lainakis, G, Kastritis, E. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment. Oncology. 2007;73(5–6):290–297.CrossRefGoogle ScholarPubMed

Cohen, HT, McGovern, FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–2490.CrossRefGoogle ScholarPubMed

Rini, BI.Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol. 2009; 27(19):3225–3234.CrossRefGoogle ScholarPubMed

Berdjis, N, Hakenberg, OW, Novotny, V. Treating renal cell cancer in the elderly. BJU Int. 2006;97(4):703–705.CrossRefGoogle ScholarPubMed

Thompson, RH, Ordonez, MA, Lasonos, A. Renal cell carcinoma in young and old patients – is there a difference?J Urol. 2008;180(4):1262–1266; discussion 1266.CrossRefGoogle Scholar

Huang, WC, Levey, AS, Serio, AM. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006;7(9):735–740.CrossRefGoogle ScholarPubMed

Shirasaki, Y, Tsushima, T, Nasu, Y. Long-term consequence of renal function following nephrectomy for renal cell cancer. Int J Urol. 2004;11(9):704–708.CrossRefGoogle ScholarPubMed

Motzer, RJ, Mazumdar, M, Bacik, J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–2540.CrossRefGoogle ScholarPubMed

Motzer, RJ, Bukowski, RM, Figlin, RA. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008;113(7):1552–1558.CrossRefGoogle ScholarPubMed

Pyrhonen, S, Salminen, E, Ruutu, M. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17(9):2859–2867.CrossRefGoogle ScholarPubMed

,Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet. 1999;353(9146):14–17.CrossRefGoogle Scholar

Fyfe, G, Fisher, RI, Rosenberg, SA. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–696.CrossRefGoogle ScholarPubMed

Klapper, JA, Downey, SG, Smith, FO. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113(2):293–301.CrossRefGoogle ScholarPubMed

McDermott, DF, Atkins, MB. Immunotherapy of metastatic renal cell carcinoma. Cancer J. 2008;14(5):320–324.CrossRefGoogle ScholarPubMed

Yang, JC, Haworth, L,Sherry, RM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5): 427–434.CrossRefGoogle ScholarPubMed

Rini, BI, Halabi, S, Rosenberg, JE. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422–5428.CrossRefGoogle ScholarPubMed

Escudier, B, Pluzanska, A, Koralewski, P. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–2111.CrossRefGoogle ScholarPubMed

Motzer, RJ, Michaelson, MD, Redman, BG. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16–24.CrossRefGoogle ScholarPubMed

Motzer, RJ, Rini, BI, Bukowski, RM. Sunitinib in patients with metastatic renal cell carcinoma. J Am Med Assoc. 2006;295(21):2516–2524.CrossRefGoogle ScholarPubMed

Motzer, RJ, Hutson, TE, Tomczak, P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2): 115–124.CrossRefGoogle ScholarPubMed

Escudier, B, Eisen, T, Stadler, WM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134.CrossRefGoogle ScholarPubMed

Hudes, G, Carducci, M, Tomczak, P. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–2281.CrossRefGoogle ScholarPubMed

Motzer, RJ, Escudier, B, Oudard, S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–456.CrossRefGoogle ScholarPubMed

Bukowski, RM, Stadler, WM, Figlin, RA. Safety and efficacy of sorafenib in elderly patients (pts) ≥ 65 years: a subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5045).

Di Lorenzo, G, Autorino, R, Bruni, G. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009; 20(9):1535–1542.CrossRefGoogle ScholarPubMed

Bellmunt, J, Negrier, S, Escudier, B. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol. 2009;69(1):64–72.CrossRefGoogle ScholarPubMed

Veldt, AA, Boven, E, Helgason, HH. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;99(2):259–265.CrossRefGoogle ScholarPubMed

Hall, R.Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer [abstract]. Proc Am Soc Clin Oncol. 2002;21:178a.Google Scholar